Clinical Research Directory
Browse clinical research sites, groups, and studies.
Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
Sponsor: I.M. Sechenov First Moscow State Medical University
Summary
Heart failure with preserved left ventricular ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Systemic low-grade inflammation is acknowledged to be a fundamental pathophysiological mechanism of HFpEF. Interventions targeting inflammatory pathway is understudied in HFpEF. Colchicine is a safe and well tolerated anti-inflammatory drug, which interferes with several steps in the inflammatory process. The drug has been extensively studied in different cardiovascular pathologies except HFpEF. We assume that colchicine decreases inflammation and reduces sST2 levels in HFpEF.
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2022-12-15
Completion Date
2025-11-01
Last Updated
2025-04-10
Healthy Volunteers
No
Interventions
Colchicine
The active treatment intervention consists of colchicine 0.5 mg twice daily that will be administrated by the investigator
Locations (2)
A Shchendrygina
Moscow, Russia
Anastasia Shchendrygina
Moscow, Russia